Evidence map›Paper›PMID 39305441›Full record

Trial reportJournal of endocrinological investigation2025

Relacorilant or surgery improved hemostatic markers in Cushing syndrome.

C Simeoli, N Di Paola, A Stigliano, P Lardo, T Kearney, E Mezosi, E Ghigo, R Giordano, C N Mariash, D M Donegan and 5 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02804750 (Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02804750 phase2completednot on this map

Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome

TypeinterventionalSponsorCorcept TherapeuticsRan2016 to 2018Enrolled35ConditionsCushing's SyndromeArmsCORT125134
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Hypercoagulability in Cushing's syndrome: past, present, future.Archives of endocrinology and metabolism · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

C SimeoliDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università "Federico II" di Napoli, Naples, Italy.
N Di PaolaDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università "Federico II" di Napoli, Naples, Italy.
A StiglianoEndocrinology, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
P LardoEndocrinology, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
T KearneySalford Royal Foundation Trust, Salford, Manchester, UK.
E Mezosi1st Department of Internal Medicine, Clinical Center, University of Pecs, Pecs, Hungary.
E GhigoDivision of Endocrinology, Diabetology and Metabolism, University of Turin, Turin, Italy.
R GiordanoDepartment of Biological and Clinical Sciences, University of Turin, Turin, Italy.
C N MariashIndiana University, Indiana University Health, Indianapolis, IN, USA.
D M DoneganIndiana University School of Medicine, Indianapolis, IN, USA.
R A FeeldersDepartment of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.
A L HandCorcept Therapeutics Incorporated, Redwood City, CA, 94065, USA.
K A AraqueCorcept Therapeutics Incorporated, Redwood City, CA, 94065, USA.
A G MoraitisCorcept Therapeutics Incorporated, Redwood City, CA, 94065, USA. amoraitis@corcept.com.ORCID http://orcid.org/0000-0001-5613-505X
R PivonelloDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Università "Federico II" di Napoli, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGlucocorticoid-mediated hypercoagulability can persist in patients with endogenous Cushing syndrome (CS) after curative surgery and may transiently worsen early postoperatively. These studies aimed to characterize coagulation markers at baseline in patients with CS and the impact of relacorilant or remission post-surgery in an open-label, phase 2 study (NCT02804750) and a retrospective, longitudinal, surgical cohort study.

methodsIn the relacorilant study, 34 patients received relacorilant (100-200 mg/day for up to 12 weeks or 250-400 mg/day for up to 16 weeks) and had postbaseline data. Coagulation markers were assessed before and during treatment. In the surgical study, conducted at "Federico II" University of Naples, Italy, coagulation markers were assessed in 30 patients before surgery and after biochemical remission.

resultsIn the relacorilant study, significant mean changes from baseline to last observed visit were reported in factor VIII (- 18.9%, P = 0.022), activated partial thromboplastin time (aPTT) (+ 1.5 s, P = 0.046), and platelet count (- 68.8*10

conclusionsSeveral coagulation markers improved in patients with CS after 3-4 months of relacorilant treatment and within an average of 6 months after surgery. Relacorilant's positive effects on coagulation markers support further investigation of its use preoperatively in patients with CS or in patients who are not eligible for surgery. CLINICAL TRIAL REGISTRATION NUMBER: NCT0280475 (registration date: 15 June 2016).

Indexed as

BiomarkersCushing SyndromeHemostasisAdultFemaleFollow-Up StudiesHumansLongitudinal StudiesMaleMiddle AgedPrognosisRetrospective StudiesBiomarkersCoagulation factorCushing syndromeHypercoagulable stateRelacorilantSurgery

Identifiers

PMID39305441
PMCPMC11876277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.